Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy—before treatment has begun, and without additional biopsies. That means patients can avoid treatments that are unlikely to help them, have a chance to enroll earlier in clinical trials of newer drugs, and may get a clearer picture of their prognosis.